| 370 | 10 | 65 |
| 下载次数 | 被引频次 | 阅读次数 |
为分析中国新疆阿克苏地区2019-2020年A(H3N2)亚型流感病毒抗原性变异及耐药情况。本文选取A(H3N2)亚型流感病毒血凝滴度≥8的毒株，用标准雪貂抗血清进行抗原性分析，利用二代测序技术对病毒基因测序后进行序列分析，通过耐药检测分析病毒对神经氨酸酶抑制剂的敏感性。抗原性分析结果显示，全部毒株为疫苗株A/Kansas/14/2017细胞株的低反应株，均为疫苗株A/HongKong/45/2019细胞株的类似株。HA和NA基因序列进化树显示与A/HongKong/45/2019属于同一分支。与同年疫苗株A/Kansas/14/2017比对，HA蛋白抗原决定簇位点氨基酸变异，分别是E62G、N91S、K92R、N121K、T135K、S137F、K144S、S159Y、K160T、N171K、I179V、R208I；受体结合位点T135K、S137F处氨基酸发生变异；133-135、483-485处减少两个潜在糖基化位点，158-160处增加1个潜在糖基化位点；HA蛋白二硫键位点保守。与同年疫苗A/Kansas/14/2017比对，NA蛋白抗原决定簇位点T329S、K344E处氨基酸发生变异；NA蛋白酶活性位点及周围催化位点、耐药位点、糖基化位点保守，二硫键C42F处发生氨基酸变异。M2蛋白S31N位点处氨基酸发生变异。本地区A(H3N2)流感病毒对神经氨酸酶抑制剂奥司他韦和扎那米韦药物敏感。总之，2019-2020年阿克苏地A(H3N2)亚型流感病毒与WHO推荐的2019-2020年北半球疫苗株A/Kansas/14/2017不匹配，而与WHO推荐2020-2021年北半球疫苗株A/HongKong/45/2019匹配性更好。还需持续做好流感病毒抗原性和耐药监测工作，及时掌握流感病毒基因特性情况，为本地区流感病毒防控提供科学依据。
Abstract：We wished to analyze the antigenic variation and drug resistance of influenza A virus subtype H3N2strains in Aksu, China, in 2019 – 2020. We selected influenza A virus subtype H3N2 strains with hemagglutination titer ≥8 and analyzed antigenicity with reference ferret anti-sera. We sequenced viral genes using second-generation technology. The susceptibility of the virus to neuraminidase inhibitors was analyzed by a drug-resistance test. Antigenicity analyses showed that all strains were low-reactive strains of the vaccine strain A/Kansas/14/2017 cell line,and that all strains were similar to the vaccine strain A/HongKong/45/2019 cell line. The phylogenetic trees of sequences of HA and NA showed that they belonged to the same branch as A/HongKong/45/2019. Compared with the vaccine strain A/Kansas/14/2017,the variations in the amino acids of the antigen sites of HA proteins were E62G,N91S,K92R,N121K,T135K,S137F,K144S,S159Y,K160T,N171K,I179V and R208I;the amino acids at receptor binding sites T135K and S137F were mutated.Two potential glycosylation sites(133– 135 and 483– 485)were reduced and one potential glycosylation site(158– 160)was increased. The disulfide bond site of HA protein was conserved. Compared with the vaccine strain A/Kansas/14/2017,the variation in amino acids occurred at the antigenic determinant cluster sites T329S and K344E in NA protein;the NA protease active site and its surrounding catalytic sites,drug-resistance sites,and glycosylation sites were conserved. Variation in amino acids occurred at the disulfide bond C42F. Variants of amino acids occurred at the S31N site of M2 protein. Influenza A virus subtype H3N2 strains in this region were sensitive to the neuraminidase inhibitors oseltamivir and zanamivir. In conclusion,the antigenicity and genetic characteristics of influenza A virus subtype H3N2 in Aksu from 2019 to 2020 have changed compared with those in the vaccine strain A/Kansas/14/2017 in the same year. The 2019–2020 Aksu subtype A(H3N2)influenza virus does not match the World Health Organization(WHO)-recommended 2019– 2020 Northern Hemisphere vaccine A/Kansas/14/2017,but matches better with the WHO-recommended2020 – 2021 Northern Hemisphere vaccine strain A/HongKong/45/2019. Studying the antigenicity and drug resistance of influenza viruses must be continued to ascertain their genetic characteristics. In this way,a scientific basis for the prevention and control of influenza viruses in Aksu can be obtained.
[1] Ramsay L C,Buchan S A,Stirling R G,Cowling B J,Feng S,Kwong J C,Warshawsky B F. The impact of repeated vaccination on influenza vaccine effectiveness:a systematic review and meta-analysis[J/OL]. BMC Med,2019,17(1):9. DOI:10.1186/s12916-018-1239-8.
[2] Lindstrom S E,Hiromoto Y,Nerome R,Omoe K,Sugita S, Yamazaki Y, Takahashi T, Nerome K.Phylogenetic analysis of the entire genome of influenza A(H3N2)viruses from Japan:evidence for genetic reassortment of the six internal genes[J/OL]. J Virol,1998,72(10):8021-8031.DOI:10.1128/jvi.72.10.8021-8031.1998.
[3] Bedford T, Suchard M A, Lemey P, Dudas G,Gregory V,Hay A J,McCauley J W,Russell C A,Smith D J,Rambaut A. Integrating influenza antigenic dynamics with molecular evolution[J/OL]. Elife,2014,3:e01914.DOI:10.7554/eLife.01914.
[4] Potter B I, Kondor R, Hadfield J, Huddleston J,Barnes J,Rowe T,Guo L,Xu X,Neher R A,Bedford T,Wentworth D E. Evolution and rapid spread of a reassortant A(H3N2)virus that predominated the 2017-2018 influenza season[J/OL]. Virus Evol,2019,5(2):vez046.DOI:10.1093/ve/vez046.
[5]周权，沈新秀，杜翠林，艾克拜尔·艾合麦提. 2010-2018年阿克苏地区流感样病例监测分析[J/OL].疾病预防控制通报，2019(03):27-30. DOI:10.13215/j.cnki.jbyfkztb.1904003.
[6]黄维娟，成艳辉，李希妍，赵翔，郭俊峰，王钊，谭敏菊，李明，隋竑弢，隗合江，陈瑶瑶，肖宁，蓝雨，王大燕，舒跃龙. 2011~2012年度中国H3N2亚型流感病毒病原学特征分析[J/OL].病毒学报，2013(03):258-264.DOI:10.13242/j.cnki.bingduxuebao.002384.
[7]成艳辉，刘佳，谭敏菊，隗合江，肖宁，李希妍，赵翔，杨磊，黄维娟，王大燕. 2017~2018监测年度中国大陆A(H1N1)pdm09亚型流感病毒抗原性和基因特性分析[J/OL].病毒学报，2019(03):431-439. DOI:10.13242/j.cnki.bingduxuebao.003543.
[8]曹蓝，鲁恩洁，陈艺韵，马钰，李魁彪，陆剑云，狄飚.2017—2018年广州市H3N2流感病毒流行及血凝素基因分子特征分析[J].中国人兽共患病学报，2019(10):899-904+921.
[9]何川，刘海涛，宋景红，张博文. 2018-2019北京市门头沟区甲型H3N2流感疫情病毒HA基因分析[J].预防医学情报杂志，2021(01):142-148.
[10]Baker A,Varghese J,Laver W,Air G,Colman P.Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus[J/OL]. Proteins,1987,2(2):111-117.DOI:10.1002/prot.340020205.
[11]Varghese J N, Colman P M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution[J/OL]. J Mol Biol,1991,221(2):473-486.DOI:10.1016/0022-2836(91)80068-6.
[12]Wedde M,Biere B,Wolff T,Schweiger B. Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2)viruses circulating between 2008-2009 and 2013-2014 in Germany[J/OL].Int J Med Microbiol,2015,305(7):762-775. DOI:10.1016/j.ijmm.2015.08.030.
[13]Allen J D, Ross T M. H3N2 influenza viruses in humans:viral mechanisms,evolution,and evaluation[J/OL]. Hum Vaccin Immunother,2018,14(8):1840-1847.DOI:10.1080/21645515.2018.1462639.
[14]Korsun N, Trifonova I, Voleva S, Grigorova I,Angelova S. Genetic characterisation of the influenza viruses circulating in Bulgaria during the 2019-2020winter season[J/OL]. Virus Genes,2021:1-12.DOI:10.1007/s11262-021-01853-w.
[15]Mu?oz E T,Deem M W. Epitope analysis for influenza vaccine design[J/OL]. Vaccine,2005,23(9):1144-1148.DOI:10.1016/j.vaccine.2004.08.028.
[16]郭元吉，程小雯.流行性感冒病毒及其实验技术[M].北京：中国三峡出版社，1997. 20-21.
[17]Weis W,Brown J H,Cusack S,Paulson J C,Skehel J J, Wiley D C. Structure of the influenza virus haemagglutinin complexed with its receptor,sialic acid[J/OL]. Nature,1988,333(6172):426-431. DOI:10.1038/333426a0.
[18]谢剑锋，沈晓娜，王美爱，杨式芹，修文琼，黄萌，张炎华，翁育伟，严延生，郑奎城. 2010-2012年福建省H3N2亚型流感病毒血凝素基因特征分析[J].中国人兽共患病学报，2013,29(12):1157-1161.
[19]张太翔，王炳军，田国华，田国宁，张金玲，侯志高，韩亮，张丽萍.流感病毒血凝素受体分子的研究进展[J].中国畜牧兽医，2010,37(02):188-191.
[20]Huang J W,Yang J M. Changed epitopes drive the antigenic drift for influenza A(H3N2)viruses[J/OL].BMC Bioinformatics,2011:S31. DOI:10.1186/1471-2105-12-s1-s31.
[21]Kawakami C,Yamayoshi S,Akimoto M,Nakamura K,Miura H,Fujisaki S,Pattinson D J,Shimizu K,Ozawa H,Momoki T,Saikusa M,Yasuhara A,Usuku S, Okubo I, Toyozawa T, Sugita S, Smith D J,Watanabe S, Kawaoka Y. Genetic and antigenic characterisation of influenza A(H3N2)viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons[J/OL]. Euro Surveill, 2019, 24(6). DOI:10.2807/1560-7917.Es.2019.24.6.1800467.
[22]Wagner R,Matrosovich M,Klenk H D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections[J/OL]. Rev Med Virol,2002,12(3):159-166.DOI:10.1002/rmv.352.
[23]李向忠，方芳，陈则.流感病毒神经氨酸酶不同区域的作用[J/OL].生命科学研究，2005(S1):59-65.DOI:10.16605/j.cnki.1007-7847.2005.s1.012.
[24]黄维娟，董丽波，张烨，温乐英，赵翔，黎满香，郭俊峰，蓝雨，李梓，王敏，董婕，郭元吉，舒跃龙. 1996~2005年中国H3N2亚型人流感病毒神经氨酸酶基因特性分析[J].病毒学报，2007(05):345-349.
[25]Hay A J,Zambon M C,Wolstenholme A J,Skehel J J,Smith M H. Molecular basis of resistance of influenza A viruses to amantadine[J/OL]. J Antimicrob Chemother,1986, 18 Suppl B:19-29. DOI:10.1093/jac/18.supplement_b.19.
[26]Zaraket H,Kondo H,Hibino A,Yagami R,Odagiri T,Takemae N,Tsunekuni R,Saito T,Myint Y Y,Kyaw Y,Oo K Y,Tin H H,Lin N,Anh N P,Hang Nle K,Mai le Q,Hassan M R,Shobugawa Y,Tang J,Dbaibo G, Saito R. Full genome characterization of human influenza A/H3N2 isolates from Asian countries reveals a rare amantadine resistance-conferring mutation and novel PB1-F2 polymorphisms[J/OL]. Front Microbiol, 2016, 7:262. DOI:10.3389/fmicb.2016.00262.
[27]McKimm-Breschkin J L. Influenza neuraminidase inhibitors:antiviral action and mechanisms of resistance[J/OL]. Influenza Other Respir Viruses,2013,7Suppl1(Suppl 1):25-36.DOI:10.1111/irv.12047.
[28]Simon B,Pichon M,Valette M,Burfin G,Richard M,Lina B, Josset L. Whole genome sequencing of A(H3N2)influenza viruses reveals variants associated with severity during the 2016-2017 season[J/OL].Viruses,2019,11(2).DOI:10.3390/v11020108.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004163
中图分类号:R373.13
引用信息:
[1]荣晓夙,周红亮,马瑞杰,等.2019-2020年阿克苏地区A(H3N2)亚型流感病毒抗原变异与耐药分析[J].病毒学报,2022,38(04):821-832.DOI:10.13242/j.cnki.bingduxuebao.004163.
2022-07-05
2022-07-05
2022-07-05